LIGANDOMICSRX, LLC

Biotech · Private

Ligandomics platform technology for global mapping of extracellular ligands and disease-selective ligands across cell types

Grants
$226K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Next-generation ligandomics technology to globally map cellular ligands of the retina$226,255
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1638SAPPHIRE BIOTECH, INC.——
1639Atalanta Therapeutics——
1640Aera Therapeutics——
1641LIGANDOMICSRX, LLC——
1642DOPHEN BIOMED, INC.——
1643T3S Technologies, Inc.——
1644MIDI, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.